BHST (BioHarvest Sciences) Total Current Assets : $7.98 Mil (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BioHarvest Sciences Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. BioHarvest Sciences's total current assets for the quarter that ended in Sep. 2024 was $7.98 Mil.

BioHarvest Sciences Total Current Assets Historical Data

The historical data trend for BioHarvest Sciences's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioHarvest Sciences Total Current Assets Chart

BioHarvest Sciences Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

0.87

2.24

5.67

4.32

9.05

BioHarvest Sciences Quarterly Data
	Oct19	Jan20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Current Assets	Get a 7-Day Free Trial															4.72	9.05	7.56	9.26	7.98

BioHarvest Sciences Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

BioHarvest Sciences's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	5.355	+	0.957	+	2.466	+	0.274
	=	9.05

BioHarvest Sciences's Total Current Assets for the quarter that ended in Sep. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2.768	+	2.026	+	3.188	+	0
	=	7.98

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

BioHarvest Sciences (NAS:BHST) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

BioHarvest Sciences's Liquidation Value for the quarter that ended in Sep. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.768	-	21.684	+	0.75 * 1.163	+	0.5 * 3.188
=	-16.45

BioHarvest Sciences Total Current Assets Related Terms

Thank you for viewing the detailed overview of BioHarvest Sciences's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BioHarvest Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioHarvest Sciences Inc (NAS:BHST) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

8MV0:Germany BHSC:Canada

Address

1140-625 Howe Street, Vancouver, BC, CAN, V6C 2T6

Website

https://www.bioharvest.com

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.